Barclays Capital Reiterates a “Overweight” Rating on AstraZeneca PLC (LON:AZN); Theravance Biopharma Has 1.32 Sentiment

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.53 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Barclays Capital restate their “Overweight” rating on AstraZeneca PLC (LON:AZN)‘s stock in a research note revealed on Monday morning.

The stock increased 0.26% or GBX 13 during the last trading session, reaching GBX 5056. About 163,046 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since January 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 31 analysts covering AstraZeneca PLC (LON:AZN), 18 have Buy rating, 3 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca PLC has GBX 7600 highest and GBX 4.57 lowest target. GBX 5100.47’s average target is 0.88% above currents GBX 5056 stock price. AstraZeneca PLC had 596 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of AstraZeneca PLC (LON:AZN) earned “Buy” rating by Cantor Fitzgerald on Tuesday, April 26. The rating was maintained by JP Morgan with “Neutral” on Friday, February 19. On Wednesday, July 26 the stock rating was maintained by Barclays Capital with “Overweight”. The stock has “Buy” rating by Deutsche Bank on Friday, April 1. Jefferies maintained AstraZeneca PLC (LON:AZN) rating on Friday, April 21. Jefferies has “Hold” rating and GBX 4900 target. On Friday, November 10 the stock rating was maintained by Kepler Cheuvreux with “Buy”. Deutsche Bank maintained AstraZeneca PLC (LON:AZN) on Monday, January 23 with “Buy” rating. Bryan Garnier & Cie maintained it with “Buy” rating and GBX 5400 target in Tuesday, February 28 report. On Monday, October 9 the stock rating was maintained by Shore Capital with “Hold”. The firm has “Hold” rating given on Tuesday, January 3 by Shore Capital.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 64.01 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 18.12 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Analysts await AstraZeneca PLC (LON:AZN) to report earnings on February, 1. They expect $0.44 EPS, down 63.64% or $0.77 from last year’s $1.21 per share. AZN’s profit will be $5.57 million for 2872.73 P/E if the $0.44 EPS becomes a reality. After $1.12 actual EPS reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -60.71% negative EPS growth.

Cormorant Asset Management Llc holds 5.74% of its portfolio in Theravance Biopharma, Inc. for 950,000 shares. Foundation Asset Management Lp owns 432,532 shares or 4.61% of their US portfolio. Moreover, Baupost Group Llc Ma has 3.97% invested in the company for 9.31 million shares. The Massachusetts-based Opaleye Management Inc. has invested 2.18% in the stock. Old West Investment Management Llc, a California-based fund reported 113,942 shares.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 EPS, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.

Ratings analysis reveals 50% of Theravance Biopharma’s analysts are positive. Out of 2 Wall Street analysts rating Theravance Biopharma, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $24.0 while the high is $40.0. The stock’s average target of $32 is 12.99% above today’s ($28.32) share price. TBPH was included in 2 notes of analysts from October 12, 2016. Robert W. Baird downgraded Theravance Biopharma, Inc. (NASDAQ:TBPH) on Wednesday, October 12 to “Underperform” rating. The firm earned “Buy” rating on Wednesday, December 21 by Needham.

The stock increased 1.11% or $0.31 during the last trading session, reaching $28.32. About 200,344 shares traded or 14.07% up from the average. Theravance Biopharma, Inc. (TBPH) has risen 89.85% since January 22, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.